Navigation Links
KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody
Date:12/10/2013

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced preliminary results of an ongoing multi-center Phase 1 study of KB004, an anti-EphA3 monoclonal antibody (mAb), which the company is developing as a treatment for hematologic malignancies. Forty-four patients with refractory disease or who were unfit for chemotherapy have been enrolled in the dose escalation portion of the study.  The experimental patient-targeted therapeutic has been well tolerated, with initial evidence of clinical activity.

(Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO)

Preliminary results of the study were presented yesterday by lead investigator, Jeffrey E. Lancet, M.D. of the H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida at the 55th American Society of Hematology Annual Meeting and Exhibition (ASH), held this week in New Orleans, Louisiana.

"We are encouraged by the results seen with KB004 to date, which has been well-tolerated at doses up to 190 mg, with mild to moderate transient infusion reactions the most common toxicity," said Dr. Lancet. "There are some signs of activity as well, including a patient with relapsed acute myeloid leukemia (AML) who had sustained remission for over 1 year."

Escalating doses of KB004 were administered as a 1 or 2 hour infusion on days 1, 8, and 15 of a 21 day cycle at incremental doses of 20, 40, 70, 100, 140, 190 and 250 mg and will thereafter increase at 33% increments up to a planned maximum of 700 mg. The primary study objective is to determine a maximum tolerated dose, which has not yet been reached. Secondary objectives included evaluation of pharmacokinetics, imm
'/>"/>

SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
2. Wyss Institute at Harvard University announces election of 2 faculty to Natl Academy of Inventors
3. Reproductive Health Matters announces publication of its latest themed issue: New development paradigm
4. Afterburn Fuel Review Announces the Launch of its New and Informative Website
5. VaxTrac Announces Continued Support for Expansion of Biometric-based Mobile Vaccine Registry Programs in Benin
6. AIBS announces winners of Faces of Biology photo competition
7. NERC announces the winner of its first photo and essay competition
8. Elsevier announces the launch of open access journal: Current Plant Biology
9. AVS Announces Its Major Award Winners of 2013
10. The Association for Molecular Pathology announces highlights of Phoenix meeting
11. EMBO announces the launch of EMBO Press
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/29/2014)... household and industrial products are in the environment – ... of them, scientists have yet to determine whether they ... toward doing that by estimating which substances people are ... in the ACS journal Environmental Science & Technology ... the risks to human health of any given substance ...
(Date:10/29/2014)... New York City on September 19, 2014, leading geneticist ... Professor of Genome Sciences and Medicine at the University ... Philosophy of Tel Aviv University, was awarded the 2014 ... addition to her honorary degree from TAU, Prof. King ... of Medicine, and for the past 18 years she ...
(Date:10/29/2014)... news release is available in German . ... like another: Gabriela Cabral and Peter Schlögelhofer at the ... Vienna and the Medical University of Vienna dived into ... revealed that these plants display an inversion of the ... in the scientific journal Nature Communications . , ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2Meiotic cell division 'the other way round' 2
... new quarterly newsletter for academic librarians and information professionals. ... developments at OUP and across the publishing world. ... and member of the Editorial Team said: ,After careful ... developed a strong and broad source of information for ...
... has been largely overlooked by the public until now. ... of 157 scientists (the Nasonia Genome Working Group) ... University of Rochester, and Stephen Richards at the Genome Sequencing ... the genomes of three parasitoid wasp species. The genomes reveal ...
... 500,000 funding for the Peninsula Dental School to pursue three ... was announced today. The first area of research will ... published evidence and the creation of new approaches to understanding ... will look at the use of virtual reality and psychological ...
Cached Biology News:Genome advances peril for pests 2Genome advances peril for pests 3Genome advances peril for pests 4University of Plymouth invests in dental research 2
(Date:10/31/2014)... Following the successful launch of On ... to introduce its new product and demonstrate its potential ... Launched in September, Formedix On Demand Services is the ... automation tools. For the first time, these market-leading tools ... introducing Formations – a revolutionary new token-based payment system ...
(Date:10/31/2014)... 31, 2014 The report "Dairy ... Formulation (Plain, Flavored, Sweetened, Unsweetened), Channel (Supermarket, Health ... Trends & Forecast to 2018," defines and segments ... and forecast of revenue and volume for plant-based ... projected to reach $14 Billion by 2018 with ...
(Date:10/31/2014)... 2014 ENVIRON , an ... today that Dr. Harvey Clewell III has rejoined ... work closely with senior professionals in ENVIRON’s Health ... serve at The Hamner Institutes for Health Sciences ... where he is Director, Center for Human Health ...
(Date:10/31/2014)... 31, 2014  Tavistock Development Co. (TDC), a ... celebrated the groundbreaking of the GuideWell Innovation Center ... The 92,000-square-foot, three-story facility is the first ... designed specifically for life sciences, health innovation, ... the 650-acre Lake Nona Medical City, near the ...
Breaking Biology Technology:Formedix to Introduce "Revolutionary" Clinical Trial Automation Software with Learning Webinar 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 3Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 4Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3GuideWell Innovation Center Groundbreaking Hosted by Tavistock Development Company at Lake Nona Medical City 2GuideWell Innovation Center Groundbreaking Hosted by Tavistock Development Company at Lake Nona Medical City 3
... silicon transistors in your computer may be replaced in ten ... scientists at the University of Gothenburg are hoping they ... Silicon is subject to certain limitations, and industry is ... sales of over USD 200 billion, and this means that ...
... Mass. , June 1 Merrimack Pharmaceuticals today announced that it will present ... Mulroy , President and Chief Executive Officer, will provide a company overview at 11:00am EDT ... , New York . , , , ... Merr i mack , ...
... LAKE CITY , June 1 Glycosan BioSystems ... gaining regulatory approval within the European Union for the use ... autologous adipose derived cells in reconstruction and aesthetic plastic surgery ... Mark as an implantable medical device.  HyStem-Rx will ...
Cached Biology Technology:Faster computers with nanotechnology 2Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference 2Glycosan BioSystems Seeks CE Mark in the European Union for HyStem-Rx, a Unique, Implantable Scaffold for Tissue Engineering 2
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
... a positive selection for creating baculovirus recombinants ... insect cells. The kit improves on the ... eliminating the time-consuming steps of plaque purification. ... with a portion of the essential open ...
... General description: Dish uses include large-scale colony-counting ... with PBA Flexys TM automated colony ... is a new product number, created to ... no availability yet, please order under the ...
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
Biology Products: